Consensus-based recommendation for surveillance of dyslipidaemia

This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.

Who is at risk for dyslipidaemia?

CAYA cancer survivors treated with

  • TBI
  • HSCT

What surveillance modality should be used and at what frequency should it be performed?

  • A fasting lipid profile
    starting no later than at the age of 40 years, and at least every 5 years subsequently a

What should be done if abnormalities are identified?

  • Evaluate other features of metabolic syndrome (including impaired glucose metabolism or diabetes mellitus, overweight and hypertension)
  • Refer to the appropriate HCP


While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.

It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.

In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.

a Timing of initiation and frequency could be guided by family history, presence of co-morbid conditions associated with dyslipidaemia risk or by national cardiovascular risk management guidelines.